L S Young
Overview
Explore the profile of L S Young including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
489
Citations
9953
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giannoudis A, Vareslija D, Sharma V, Zakaria R, Platt-Higgins A, Rudland P, et al.
ESMO Open
. 2022 Nov;
7(6):100636.
PMID: 36423363
Background: Immune checkpoint inhibition is an established treatment in programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative (TN) breast cancer (BC). However, the immune landscape of breast cancer brain metastasis (BCBM) remains...
2.
Rowlands D, Ito M, Mangham D, Reynolds G, Herbst H, Hallissey M, et al.
Br J Cancer
. 2016 May;
114(12):e15.
PMID: 27228295
No abstract available.
3.
Redmond A, Byrne C, Bane F, Brown G, Tibbitts P, OBrien K, et al.
Oncogene
. 2014 Oct;
34(29):3871-80.
PMID: 25284587
Breast cancer resistance to endocrine therapies such as tamoxifen and aromatase inhibitors is a significant clinical problem. Steroid receptor coactivator-1 (SRC-1), a coregulatory protein of the oestrogen receptor (ER), has...
4.
Elmetwali T, Young L, Palmer D
Cell Death Dis
. 2014 May;
5:e1213.
PMID: 24810049
CD40-induced signalling through ligation with its natural ligand (CD40L/CD154) is dependent on recruitment of TRAF molecules to the cytoplasmic domain of the receptor. Here, we applied the yeast two-hybrid system...
5.
Collins D, Cocchiglia S, Tibbitts P, Solon G, Bane F, McBryan J, et al.
Oncogene
. 2014 Jan;
34(4):525-30.
PMID: 24469058
Treatment with tyrosine kinase inhibitors (TKIs) including trastuzumab has revolutionized the management of HER2-positive breast cancer. Recent evaluation of clinical trial data suggests that a subset of HER2/ER double-positive cancers...
6.
Brennan K, McSherry E, Hudson L, Kay E, Hill A, Young L, et al.
Oncogene
. 2012 Jul;
32(22):2799-804.
PMID: 22751120
Junctional adhesion molecule-A (JAM-A) is a membranous cell-cell adhesion protein involved in tight-junction formation in epithelial and endothelial cells. Its overexpression in breast tumors has recently been linked with increased...
7.
deBlacam C, Byrne C, Hughes E, McIlroy M, Bane F, Hill A, et al.
Br J Cancer
. 2011 Jun;
105(1):118-23.
PMID: 21654685
Background: Cutaneous melanoma is an aggressive disease. S100beta is an established biomarker of disease progression; however, the mechanism of its regulation in melanoma is undefined. Methods: Expression of HOXC11 and...
8.
Ma Y, Collins S, Young L, Murray P, Woodman C
Br J Cancer
. 2011 Apr;
104(9):1500-4.
PMID: 21487403
Background: To prove a causal link between an epigenetic change and an environmental or behavioural risk factor for a given disease, it is first necessary to show that the onset...
9.
Steele J, Rao A, Marsden J, Armstrong C, Berhane S, Billingham L, et al.
Gene Ther
. 2011 Feb;
18(6):584-93.
PMID: 21307889
This trial tested a dendritic cell (DC) therapeutic cancer vaccine in which antigen is loaded using a novel non-viral transfection method enabling the uptake of plasmid DNA condensed with a...
10.
Shah K, Young L
Clin Microbiol Infect
. 2009 Oct;
15(11):982-8.
PMID: 19874382
Subsequent to its discovery over 45 years ago, Epstein-Barr virus (EBV) has been associated with numerous human carcinomas. Approximately 95% of the world's population sustain an asymptomatic life-long EBV infection....